| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
phase 2 data readout example | Phase 2 | — | Subscribe to access the data. | Small Molecules | Oncology | ||
phase 2 data readout example | Phase 2 | — | Subscribe to access the data. | Small Molecules | Oncology | ||
phase 2 data readout example | Phase 2 | — | Subscribe to access the data. | Small Molecules | Oncology |
Recent Updates
Recently added Catalysts
Allarity Therapeutics, Inc.$1.17
-0.09 (-7.5%)
D 35Pipeline Score Fair Value Pharma · Commercial
Market Cap
26.89 M
EPS
-0.72
P/E Ratio
-2.34 $
Value Trade
216.53 K
SEC Financials
Q1 2026Dilution Risk
50%Revenue
25.00 K
R&D Expenses
1.30 M
Operating CF
-4.49 M
Total Assets
34.92 M
Total Liabilities
28.00 M
Equity
6.92 M
D/E Ratio
12,345
18 %
Week
23.78 %
1 Month
68.57 %
3 Month
77 %
6 Month
-100 %
5 Year
-100 %
All Time
Cash Data
Cash Position
19.81 M
Monthly Burn
1.50 M
Runway
11.6 mo
Burn Trend
SEC Filing
May 15, 2026
Overview
Volume
103.17 K
52 Week Range
0.77 - 2.35
% held by Insiders
5.54 %
% held by Institutions
5.97 %
Enterprise Value
18.57 M
Total Shares
15.83 M
Short %
0.51 %
Float Shares
15.79 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Allarity Therapeutics, Inc.
341Total events
5Upcoming
80Tier-1 (high impact)
2020 – 2027Coverage
Upcoming catalysts 5
2026
T3Enrollment Update
Enrollment continuing in new Phase 2 protocol; critical data expected by end of 2026
Event history 336
Jul 7, 2026
▲Manufacturing MilestoneCMC / Inspection
Allarity Therapeutics obtains CLIA Certificate of Registration for in-house laboratory
Jul 7, 2026
◆Enrollment UpdatestenoparibTrial
Phase 2 trial of stenoparib in combination with temozolomide for relapsed SCLC currently enrolling
relapsed small cell lung cancer (SCLC)source ↗
Q3 2026
●Manufacturing MilestonestenoparibCMC / Inspection
Phase 3-ready API manufacturing campaign on track for Q3 2026 completion
Jul 2026
▲Patent GrantedstenoparibIP / Competition
Expected formal grant of stenoparib DRP test patent
Q3 2026
◆Timing GuidancestenoparibPresentation
Significant clinical data expected by late summer 2026
advanced, platinum-resistant or platinum-ineligible ovarian cancersource ↗
Q3 2026
◆Topline ReadoutstenoparibClinical Data
Critical data expected by end of summer 2026 for pivotal registration trial
ovarian cancersource ↗
Jun 30, 2026
▲Patent GrantedstenoparibIP / Competition
Patent protection secured for stenoparib DRP in Europe and Australia into 2039
Jun 18, 2026
●Poster PresentationstenoparibPresentation
Trial-in-Progress poster presentation at ESMO Gynaecological Cancers Congress 2026
advanced platinum-resistant or platinum-ineligible ovarian cancersource ↗
Jun 18, 2026
●Enrollment UpdatestenoparibTrial
Phase 2 trial of stenoparib in combination with temozolomide currently enrolling patients across multiple VA sites in the US
relapsed small cell lung cancersource ↗
May 15, 2026
▲Patent GrantedstenoparibIP / Competition
USPTO Notice of Allowance for stenoparib DRP companion diagnostic patent
May 11, 2026
◆Oral PresentationstenoparibPresentation
CEO presents at Precision Medicine Forum Europe 2026 on stenoparib dual inhibition and DRP biomarker
cancersource ↗
Drug Pipeline Intelligence
D35
Pipeline Score $13M
Pipeline ValueFair Value
Valuation Signal4
Drugs Scored1.6x
rNPV / MCap Top 48%
Micro Cap (rank 475 of 911)
Percentile RankAllarity Therapeutics, Inc. faces pipeline headwinds (35/100), with $778M risk-adjusted pipeline value, led by PARP inhibitor 2X-121 in Metastatic Breast Cancer (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PARP inhibitor 2X-121 Small molecule | Metastatic Breast Cancer | Phase 2 | NCT03562832 | 10% | $514M | COMPLETED | 20 | - | - | Aug 1, 2024 | - | Jan 23, 2025 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
stenoparib Fast Track | ovarian cancer | Phase 2 | 2026-04-21 | the highest stenoparib DRP scores are associated with enhanced overall survival in patients treated with stenoparib Read More | Allarity Therapeutics Presents Two AACR 2026 Posters Highlighting Stenoparib's Potential in Colorectal Cancer as well as New Predictive Data Linking DRP and Overall Survival in Ovarian Cancer - New AACR data highlight st Read More | |
stenoparib Fast Track | ovarian cancer | Phase 2 | 2026-04-21 | the highest stenoparib DRP scores are associated with enhanced overall survival in patients treated with stenoparib Read More | Allarity Therapeutics Presents Two AACR 2026 Posters Highlighting Stenoparib's Potential in Colorectal Cancer as well as New Predictive Data Linking DRP and Overall Survival in Ovarian Cancer - New AACR data highlight st Read More | |
stenoparib Fast Track | ovarian cancer | Phase 2 | 2026-04-21 | the highest stenoparib DRP scores are associated with enhanced overall survival in patients treated with stenoparib Read More | Allarity Therapeutics Presents Two AACR 2026 Posters Highlighting Stenoparib's Potential in Colorectal Cancer as well as New Predictive Data Linking DRP and Overall Survival in Ovarian Cancer - New AACR data highlight st Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ALLR
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
ALLR Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ALLR▼ -5.8%on this news
Allarity Therapeutics Announces CLIA Certification, Clearing the Path for Advancing DRP® Testing for FDA Registration
Allarity Therapeutics has achieved CLIA certification for its in-house laboratory, enabling it to conduct Drug Response Predictor (DRP) testing necessary for FDA registration of its lead agent, stenoparib. This certification allows Allarity to streamline operations, reduce turnaround times, and position itself as a key partner for European firms in U.S. clinical trials. The initiative supports the company's goal of advancing stenoparib for treating advanced ovarian cancer.
Read more →ALLRAllarity Therapeutics Announces the Grant of Essential U.S. Patent for Its Stenoparib DRP® Companion Diagnostic
Allarity Therapeutics has received a key U.S. patent for its stenoparib-specific Drug Response Predictor (DRP®) companion diagnostic, extending exclusivity until April 2042. This patent is crucial for the company's strategy to identify patients who will benefit most from stenoparib treatment, particularly in ovarian cancer. The patent also protects methods for predicting clinical benefits based on gene-expression profiles.
Read more →ALLR▲ +6.7%on this news
Allarity Therapeutics to Present Trial-in-Progress Poster on Phase 2 Stenoparib Trial at ESMO Gynaecological Cancers Congress 2026
Allarity Therapeutics announced that it will present a Trial-in-Progress poster on its Phase 2 trial of stenoparib at the ESMO Gynaecological Cancers Congress 2026. The trial focuses on patients with advanced platinum-resistant or platinum-ineligible ovarian cancer. The presentation aims to showcase the study's design and clinical rationale, emphasizing the urgent need for new treatment options in this patient population.
Read more →ALLR▼ -10.6%on this news
Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers
Allarity Therapeutics reported its first-quarter results for 2026, highlighting progress in the development of stenoparib for various cancers. The company has received FDA Fast Track designation for stenoparib's use in advanced ovarian cancer and is expanding trials in relapsed small cell lung cancer. Financially, Allarity maintained a strong position with $29.8 million in cash and noted a reduced net loss per share compared to the prior year. Additionally, Allarity received a Notice of Allowance for a new companion diagnostic patent, potentially extending the drug's market exclusivity.
Read more →ALLRCopyright 2023 Allarity Therapeutics. All rights reserved. Nasdaq: ALLR Dual inhibition of PARP and WNT: A novel drug - biomarker combination in clinical trials Thomas Jensen, CEO 2 Allarity Therapeutics Legal Statement
Allarity Therapeutics has presented information on its proprietary gene expression technology and their drug stenoparib, which targets both PARP and the WNT pathway. Stenoparib has demonstrated a favorable profile for treating advanced ovarian cancer, showing durable clinical benefits. The company is currently enrolling patients in two new Phase 2 clinical trials while acknowledging various risks linked to funding and regulatory approvals. Forward-looking statements highlight potential uncertainties in the results of these clinical studies.
Read more →ALLRAllarity Therapeutics CEO to Present at Precision Medicine Forum Europe 2026 in Stockholm
Allarity Therapeutics, a clinical-stage biopharma company, announced that its CEO, Thomas Jensen, will present at the Precision Medicine Forum Europe 2026 in Stockholm. Jensen will discuss the dual inhibition mechanism of stenoparib, a drug showing potential for treating multiple cancer types. The presentation will include insights on the Stenoparib DRP®, which is designed to identify patients likely to benefit from the treatment. This forum presents an opportunity for Allarity to highlight its clinical development efforts and engage in discussions about potential partnerships.
Read more →ALLR▲ +5.7%on this news· ran to +20% by day 3shared move
Allarity Therapeutics Advances Stenoparib Toward Pivotal Development with Phase 3 Manufacturing Campaign - Phase 3 manufacturing campaign on track for completion no later than third quarter 2026, supporting expected pivo
Allarity Therapeutics has reported that the Phase 3 manufacturing campaign for its drug stenoparib is progressing as planned, aiming for completion by the third quarter of 2026. This development is crucial for advancing stenoparib toward pivotal clinical trials for advanced ovarian cancer, especially with its recent FDA Fast Track designation. Moreover, Allarity has reported that all payments related to manufacturing have been fulfilled, alleviating concerns about future cash outlays. The company is optimistic about stenoparib's therapeutic potential based on encouraging survival data from previous studies.
Read more →ALLRAllarity Therapeutics Announces that the Stenoparib DRP® Test Has Received a Notice of Allowance from the US Patent and Trademark Office
Allarity Therapeutics announced that the USPTO has issued a Notice of Allowance for its stenoparib DRP® test patent. This patent, expected to be granted within three months, will provide exclusivity for stenoparib in conjunction with the DRP test until at least 2039. The patent aims to enhance the commercial potential of stenoparib by enabling better patient selection for treatment.
Read more →ALLR▲ +10.4%on this news
Allarity Therapeutics Presents Two AACR 2026 Posters Highlighting Stenoparib's Potential in Colorectal Cancer as well as New Predictive Data Linking DRP and Overall Survival in Ovarian Cancer - New AACR data highlight st
Allarity Therapeutics announced two posters at the AACR 2026 meeting showcasing data on stenoparib, a dual inhibitor, in colorectal and ovarian cancers. The posters highlight its mechanism of action and the positive association of the Drug Response Predictor (DRP) with overall survival in ovarian cancer patients. This data suggests a promising role for stenoparib in treating these significant cancer indications, emphasizing the importance of personalized treatment approaches. Both posters are now accessible on Allarity's website for further review.
Read more →ALLRAllarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress - Strengthened financial position through disciplined cost management, with a year-end 2025 cash position of $14.7 million and runway
Allarity Therapeutics announced its financial results for the year ended December 31, 2025, reporting a cash position of $14.7 million and a reduction in total liabilities. The company highlighted significant clinical milestones, including the FDA's Fast Track designation for its drug stenoparib and the initiation of a new Phase 2 clinical trial protocol for ovarian cancer. Despite a year-over-year improvement in net loss by approximately $4.5 million, the company reported low annual revenue of $320,000.
Read more →ALLR▲ +21.6%on this news
Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and Commercialization - Extends Company Cash Runway into Mid-2028 - Financing Expected to Fund Completion of
Allarity Therapeutics has successfully closed a $20 million financing round aimed at advancing its drug, stenoparib, towards FDA approval and eventual commercialization. This financing is structured as non-convertible debt and is expected to extend the company's cash runway into mid-2028. The funds will primarily support the completion of a Phase 2 clinical trial for advanced ovarian cancer and facilitate preparations for a pivotal trial. CEO Thomas Jensen emphasized the financing's role in enhancing both clinical development and the company's strategic initiatives.
Read more →ALLR▲ +8.7%on this news· ran to +27% by day 1
Allarity Therapeutics Doses First Patients in VA-Funded Phase 2 Trial Focused on Small Cell Lung Cancer with High Unmet Need
Allarity Therapeutics has initiated dosing of the first patients in a Phase 2 trial for stenoparib combined with temozolomide, targeting relapsed small cell lung cancer (SCLC). Funded by the U.S. Department of Veterans Affairs, the trial aims to address significant unmet medical needs in this patient population. Stenoparib's dual action may enhance treatment efficacy while minimizing toxicity, offering hope for better outcomes in SCLC.
Read more →ALLR▼ -8.1%on this news
Allarity Therapeutics announces that its collaborative Phase 2 trial with the United States Veteran’s Administration Combining Stenoparib with Temozolomide in Relapsed Small Cell Lung Cancer is Now Open for Enrollment
Allarity Therapeutics has opened enrollment for a Phase 2 clinical trial evaluating stenoparib in combination with temozolomide for relapsed small cell lung cancer. Conducted in collaboration with the U.S. Department of Veterans Affairs, the trial aims to assess safety and efficacy while utilizing a blood-based biomarker for patient selection. Stenoparib's favorable safety profile and unique mechanism may provide new treatment options for patients with limited alternatives.
Read more →ALLR▲ +6.9%on this news
Allarity Therapeutics Issues 2025 End of Year CEO Letter to Shareholders
Allarity Therapeutics' CEO letter highlights the company's progress in 2025, focusing on the development of stenoparib, a dual PARP and WNT pathway inhibitor. The company has achieved FDA Fast Track Designation for stenoparib and is expanding its clinical applications to other cancers, including recurrent Small Cell Lung Cancer. Financially, Allarity has strengthened its position while maintaining a disciplined operating model. Looking ahead to 2026, the company aims to deepen its focus on stenoparib's approval and explore additional therapeutic opportunities.
Read more →ALLRAllarity Therapeutics Provides Third Quarter 2025 Financial Results and Provides Business Updates
Allarity Therapeutics reported its third quarter 2025 financial results, highlighting significant achievements such as FDA Fast Track designation for its drug stenoparib in advanced ovarian cancer. The company also revealed that the median overall survival for patients in a Phase 2 trial now exceeds 25 months. Allarity continues to enhance its Drug Response Predictor (DRP) platform through new agreements and collaborations, with ongoing trials aimed at expanding stenoparib's applications in treating various hard-to-treat cancers. Financially, the company ended the quarter with a solid cash position, supporting operational sustainability through 2026.
Read more →ALLR▲ +15.6%on this news
Allarity Therapeutics Presents New Phase 2 Clinical Data for Stenoparib/2X-121 Showing Landmark Median Overall Survival Has Now Surpassed 25 Months
Allarity Therapeutics presented new Phase 2 clinical data indicating that the median Overall Survival for patients with platinum-resistant ovarian cancer receiving stenoparib/2X-121 has surpassed 25 months. This data, showcased at the AACR conference, highlights the drug's potential benefits for patients with varying BRCA statuses. The results suggest a significant improvement over existing therapies.
Read more →ALLRAllarity Therapeutics CEO to Present at Biomarkers & Precision Medicine 2025
Allarity Therapeutics announced that CEO Thomas Jensen will present at the Biomarkers & Precision Medicine 2025 conference in London. He will discuss the company's innovative DRP companion diagnostic platform and its dual-targeted cancer treatment, stenoparib. Jensen will also be available for individual meetings to explore business development opportunities.
Read more →ALLR▲ +51.9%on this news
Allarity Therapeutics Granted FDA Fast Track Designation for Stenoparib for the Treatment of Advanced Ovarian Cancer
Allarity Therapeutics has received FDA Fast Track designation for stenoparib, a dual PARP and WNT pathway inhibitor, aimed at treating advanced ovarian cancer. This designation allows for expedited development and review processes, reflecting the significant unmet medical need in this area. The company has also initiated a Phase 2 clinical trial to evaluate stenoparib's effectiveness in patients with recurrent, platinum-resistant ovarian cancer.
Read more →ALLRAllarity Therapeutics Provides Second Quarter 2025 Update, Highlighting Clinical Progress, IP Expansion, and New Partnerships
Allarity Therapeutics reported significant progress in its Phase 2 clinical trial for stenoparib, a dual PARP and WNT pathway inhibitor for ovarian cancer. The company also expanded its intellectual property portfolio by securing an Australian patent and formed a new partnership with a European biotech firm. Financially, Allarity has reduced liabilities and maintained a solid cash position, positioning itself well for future milestones.
Read more →ALLRAllarity Therapeutics Announces New Licensing and Laboratory Services Agreement to Expand DRP® Platform Utilization
Allarity Therapeutics has signed a commercial agreement with a European biotechnology company, granting a non-exclusive global license for its proprietary DRP® algorithms in breast cancer. The agreement includes laboratory services from Allarity's Medical Laboratory in Denmark, aimed at supporting precision oncology solutions. This partnership is expected to enhance the application of Allarity's technology without significantly impacting its financial outlook.
Read more →ALLRAllarity Therapeutics Announces Appointment of Jeff Ervin as Chief Financial Officer
Allarity Therapeutics has appointed Jeff Ervin as its new Chief Financial Officer, succeeding Alexander Epshinsky. Ervin brings nearly two decades of experience in healthcare and biotech, having previously served as Co-CFO at DayDayCook and CEO at IMAC Holdings. His expertise is anticipated to support Allarity's financial strategy and clinical development of stenoparib.
Read more →ALLRAllarity Therapeutics Receives Australian Patent Acceptance Notice for Stenoparib DRP® Companion Diagnostic
Allarity Therapeutics has announced the acceptance of its patent application for the DRP® companion diagnostic specific to stenoparib by IP Australia. This patent covers 40 claims and is a significant step in the company's strategy for international commercialization. The patent will be advertised officially, followed by a three-month opposition period. CEO Thomas Jensen emphasized the importance of this achievement in securing global IP protection as they advance stenoparib through Phase 2 trials.
Read more →ALLRAllarity Therapeutics Announces Dosing of Second Patient in New Phase 2 Trial of Stenoparib in Advanced Ovarian Cancer
Allarity Therapeutics has dosed the second patient in its Phase 2 trial of stenoparib for advanced ovarian cancer. The trial targets patients who are platinum-resistant or ineligible, addressing a significant unmet need. The rapid enrollment suggests strong investigator engagement and builds on previous data showing stenoparib's clinical benefits. The trial also aims to advance Allarity's Drug Response Predictor companion diagnostic.
Read more →ALLR▼ -5.3%on this news
Allarity Therapeutics Announces Changes to Board of Directors
Allarity Therapeutics has announced the appointment of Jesper Høiland to its Board of Directors, replacing Joseph Vazzano, who will resign at the end of June 2025. Høiland, a seasoned industry leader with over 30 years of experience, has served as a strategic consultant for Allarity since October 2024. His expertise is anticipated to aid in the commercialization phase of stenoparib, a dual PARP and WNT pathway inhibitor, as the company prepares for further clinical development.
Read more →ALLRAllarity Therapeutics Announces Research Collaboration with Indiana Biosciences Research Institute to Further Advance Understanding of Stenoparib’s Unique, Dual Therapeutic Mechanism of Action
Allarity Therapeutics has announced a research collaboration with the Indiana Biosciences Research Institute to deepen the understanding of stenoparib's dual mechanism of action. Stenoparib is a novel inhibitor targeting PARP and WNT pathways, which may enhance its efficacy against resistant cancers. This collaboration aims to support ongoing clinical trials and potential future marketing approvals.
Read more →ALLRAllarity Therapeutics Announces First Patient Enrolled in New Phase 2 Clinical Trial Protocol of Stenoparib in Advanced Ovarian Cancer
Allarity Therapeutics has announced the enrollment of the first patient in a new Phase 2 clinical trial protocol for stenoparib, targeting advanced ovarian cancer. This trial is intended to build on earlier promising results and aims to provide a safer treatment alternative to traditional chemotherapy. The design incorporates insights from oncologists to enhance patient outcomes, particularly using the Drug Response Predictor (DRP) diagnostic tool. Key goals include evaluating efficacy and safety while aligning with FDA initiatives for improved treatment pathways.
Read more →ALLRAllarity Therapeutics Announces Participation in Pharma Partnering Summit US
Allarity Therapeutics, Inc. (NASDAQ: ALLR) announced its participation in the Pharma Partnering Summit US, where CEO Thomas Jensen will discuss the company's advancements regarding stenoparib, a dual-targeted cancer treatment. The event, scheduled for May 14-15 in San Diego, will provide a platform for one-on-one meetings with executives in the biotech and pharmaceutical industries. The company emphasizes the potential of stenoparib alongside its proprietary Drug Response Predictor (DRP®) diagnostic to optimize patient outcomes.
Read more →ALLRAllarity Therapeutics Provides First Quarter 2025 Update, Highlighting Continued Stenoparib Benefit and Upcoming Trial Enrollment
Allarity Therapeutics provided a first-quarter update for 2025, highlighting continued clinical benefits from stenoparib in ovarian cancer treatment, with patients remaining on therapy for over 19 months. The company is launching two trials, one funded by the U.S. Veterans Administration for small cell lung cancer and another focusing on platinum-resistant ovarian cancer. Financially, Allarity ended the quarter with about $27 million in cash while implementing a share repurchase program. The company also resolved prior regulatory issues with the SEC and dismissed pending shareholder litigation.
Read more →ALLR▲ +5.6%on this news
Allarity Therapeutics Presents Novel Drug Response Predictor—DRP —for Daratumumab in Multiple Myeloma at AACR 2025
Allarity Therapeutics has introduced a novel Drug Response Predictor (DRP) for daratumumab, aimed at enhancing treatment outcomes for multiple myeloma patients. The DRP identifies patients who are more likely to benefit from the drug based on specific gene expression patterns. This development showcases the versatility of Allarity's DRP technology, now extending to antibody therapies. The findings will be presented at the AACR Annual Meeting, further advancing potential collaborations in precision diagnostics.
Read more →ALLR▼ -9.9%on this news· ran to -21% by day 3
Allarity Therapeutics Reports Full Year 2024 Financial Results and Provides a Business Update
Allarity Therapeutics reported strong financial results for 2024 with a cash position of $20.9 million, expected to support its clinical trials through 2027. The company plans to initiate enrollment for a Phase 2 trial in ovarian cancer and a new trial for small cell lung cancer in 2025. Stenoparib, a dual PARP/WNT pathway inhibitor, has shown promising results with some patients remaining on treatment for over 17 months. The company has also made strategic realignments to focus its efforts on stenoparib, enhancing its potential for future regulatory approval.
Read more →ALLRAllarity Therapeutics Launches Comprehensive Effort to Combat Potential Illegal Naked Short Selling of Its Shares
Allarity Therapeutics has announced a partnership with Shareholder Intelligence Services to investigate potential illegal naked short selling and trading irregularities of its shares. This action reflects the company's commitment to safeguarding shareholder value and ensuring fair trading practices. CEO Thomas Jensen emphasized the importance of maintaining trust in the market as the company continues its clinical development of stenoparib, an innovative cancer treatment. The collaboration with ShareIntel aims to monitor trading activities and take legal recourse if market manipulation is uncovered.
Read more →ALLRAllarity Therapeutics Announces Presentation of Phase 2 Clinical Data from Ongoing Trial in Advanced Ovarian Cancer Patients at the 2025 Annual Meeting for the Society of Gynecologic Oncology
Allarity Therapeutics presented Phase 2 clinical data for stenoparib at the SGO 2025 Annual Meeting, highlighting its efficacy in advanced ovarian cancer patients. The study involved heavily pre-treated individuals, many of whom were platinum-resistant, with findings showing significant clinical benefits, including durable responses in patients without BRCA mutations. Notably, stenoparib was well-tolerated and did not induce typical PARP inhibitor toxicities. This trial positions stenoparib as a promising candidate for further development in challenging cases of ovarian cancer.
Read more →ALLR▼ -11.5%on this newsshared move
Allarity Therapeutics Announces Final Settlement with the U.S. Securities and Exchange Commission
Allarity Therapeutics has announced a final settlement with the U.S. Securities and Exchange Commission regarding past disclosures related to its New Drug Application for Dovitinib. This settlement, reached without admission or denial of findings, resolves prior investigations into violations under securities laws. The company will pay a civil penalty of $2.5 million but is not anticipating any negative impact on its ongoing clinical programs. With all legal matters behind it, Allarity aims to concentrate on advancing stenoparib, its dual PARP/Wnt pathway inhibitor for cancer treatment.
Read more →ALLRAllarity Therapeutics Announces Phase 2 Trial of Stenoparib in Combination with Temozolomide for Recurrent Small Cell Lung Cancer Fully Funded by the US Veterans Administration
Allarity Therapeutics has announced a Phase 2 trial to evaluate the combination of stenoparib and temozolomide for treating recurrent Small Cell Lung Cancer (SCLC). This trial, fully funded by the U.S. Veterans Administration, will assess the safety and efficacy of this combination therapy in approximately 65 patients across 11 VA medical centers. The approach aims to leverage the unique mechanisms of stenoparib, which inhibits both PARP and tankyrase, potentially providing a safer and more effective treatment option for patients who have not responded to frontline therapies. The study builds on prior evidence suggesting that this combination could improve response rates in SCLC patients.
Read more →ALLR▲ +10.2%on this news· ran to +30% by day 3shared move
Allarity Therapeutics Announces Board Authorization of $5 Million Share Repurchase Program
Allarity Therapeutics has announced the authorization of a $5 million share repurchase program, which highlights the company’s confidence in its future and commitment to deliver value to stakeholders. The financial stability allows Allarity to conduct this program without impacting its runway, which extends into 2026. The company's ongoing development of stenoparib, a dual PARP/Wnt pathway inhibitor, remains the focus as they prepare for patient enrollment in upcoming clinical trials targeted at advanced ovarian cancer.
Read more →ALLR▲ +10.2%on this news· ran to +25% by day 3shared move
Allarity Therapeutics Announces Dismissal of Securities Class Action Lawsuit
Allarity Therapeutics announced the dismissal of a securities class action lawsuit against the company in the United States District Court for the Southern District of New York. The lawsuit alleged false statements regarding regulatory prospects for the Dovitinib New Drug Application, but Allarity consistently asserted these claims were unfounded. Following the dismissal, Allarity's CEO expressed relief, indicating the company can now concentrate on progressing stenoparib and its companion diagnostic in clinical trials for advanced ovarian cancer.
Read more →ALLR▼ -14%on this news· ran to -26% by day 1shared move
Allarity Therapeutics to Begin Enrollment for New Phase 2 Protocol to Advance Stenoparib Toward FDA Approval in Advanced Ovarian Cancer Patients
Allarity Therapeutics is set to begin patient enrollment for a new Phase 2 clinical trial of stenoparib aimed at treating advanced ovarian cancer, following approval of the trial protocol. This trial is expected to yield critical data for pursuing FDA approval by summer 2026, with insights from leading oncologists informing its design. Encouraging preliminary data shows patients have demonstrated significant durability on stenoparib, highlighting its potential as an alternative to traditional chemotherapy.
Read more →ALLRAllarity Therapeutics Announces Expansion of Phase 2 Clinical Trial to Accelerate Development of Stenoparib in Advanced Ovarian Cancer
Allarity Therapeutics has announced the expansion of its Phase 2 clinical trial for stenoparib, targeting advanced ovarian cancer. The trial aims to refine the Drug Response Predictor (DRP) technology and enhance patient selection for better treatment outcomes. Patient enrollment is expected to begin in the first half of 2025, with a focus on patients with advanced, recurrent disease. The trial is anticipated to advance stenoparib's regulatory approval efforts based on promising prior clinical data.
Read more →ALLR▼ -16.3%on this news
Allarity Therapeutics Announces Filing of Form 8-K Regarding Settlement Agreement in Principle with SEC
Allarity Therapeutics has filed a Form 8-K with the SEC regarding an agreement in principle to resolve an ongoing SEC investigation related to its prior disclosures about FDA meetings. The company asserts that this settlement allows greater focus on advancing stenoparib, a treatment for advanced ovarian cancer. Although positive about the settlement's potential, Allarity cautions that final agreement and approval by the SEC are still pending. Stenoparib has shown promising early results in clinical trials, but the company acknowledges ongoing risks related to operational execution and regulatory approval.
Read more →ALLRAllarity Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. November 12, 2024 Deadline to file Lead Plaintiff Motion
Allarity Therapeutics, Inc. is facing a class action lawsuit filed by the Portnoy Law Firm on behalf of investors who purchased securities between May 17, 2022, and July 19, 2024. The lawsuit alleges that the company issued materially false statements regarding its business operations and compliance, particularly related to the Dovitinib NDA. This misconduct reportedly led to increased risk of regulatory scrutiny and enforcement actions. Investors have until November 12, 2024, to file a motion to be named lead plaintiff.
Read more →ALLR▼ -8.3%on this news
Allarity Therapeutics Reports Key Progress in Phase 2 Stenoparib Trial and Strategic Corporate Advancements
Allarity Therapeutics has reported significant progress in its Phase 2 trial of stenoparib for advanced ovarian cancer, with two patients showing treatment benefits for over 14 months. The company has a favorable cash position to support further clinical advancement towards FDA approval. Additionally, the expansion of Allarity Medical Laboratory into revenue-generating services marks a strategic enhancement for the company, leveraging its capabilities for external biotech clients.
Read more →ALLRAllarity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Recent Operational Highlights
Allarity Therapeutics reported its third-quarter financial results for 2024, highlighting a strong cash balance of $18.5 million and regained NASDAQ compliance. The company is making progress in the Phase 2 trial for stenoparib with two patients achieving over one year of treatment. Recent appointments of experienced leaders aim to drive further development and FDA regulatory efforts. However, the company posted a significant net loss primarily due to an impairment charge.
Read more →ALLRALLARITY ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Allarity Therapeutics, Inc. and Encourages Investors to Contact the Firm
A class action lawsuit has been filed against Allarity Therapeutics in the Southern District of New York for allegedly making false statements during the Class Period from May 17, 2022, to July 19, 2024. The complaint accuses the company and its former officers of overstating the regulatory prospects of the Dovitinib NDA and engaging in misconduct. Investors have until November 12, 2024, to apply to be appointed as lead plaintiffs. The lawsuit raises concerns of significant legal and reputational risks for Allarity.
Read more →ALLRAllarity Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. November 12, 2024 Deadline to file Lead Plaintiff Motion.
Allarity Therapeutics, Inc. is facing legal challenges as the Portnoy Law Firm announces a class action for investors who purchased securities between May 17, 2022, and July 19, 2024. The firm claims that the company issued false and misleading statements about its business practices, particularly regarding regulatory issues tied to the Dovitinib NDA. Those affected have until November 12, 2024, to file a lead plaintiff motion. The allegations include misleading public statements and improper conduct related to the company’s regulatory filings, resulting in significant risks and potential damages.
Read more →ALLRAllarity Therapeutics to be Granted European Patent for DRP Companion Diagnostic for Stenoparib
Allarity Therapeutics has announced that the European Patent Office intends to grant a patent for its Drug Response Predictor (DRP) companion diagnostic specific to the cancer therapy stenoparib. This patent is a significant milestone that could strengthen Allarity's market presence and enhance the identification of patients who may benefit most from stenoparib treatment. The company is also pursuing patent applications in several other countries, including the US, Japan, and Australia. The dual-targeted nature of stenoparib likely positions the drug as a key treatment option for ovarian cancer patients, aligning with Allarity's commitment to personalized cancer therapy.
Read more →ALLRAllarity Therapeutics, Inc. Class Action Alert: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York against Allarity Therapeutics, Inc.
Allarity Therapeutics, Inc. is facing a federal securities class action lawsuit filed in the Southern District of New York. The complaint alleges that the company made false statements regarding its Dovitinib New Drug Application and failed to disclose material adverse facts, leading to potential regulatory scrutiny. Additionally, the termination of the CEO and receipt of a Wells Notice from the SEC have raised concerns about the company's future. Investors have been advised to contact the law firm representing the class action for more information.
Read more →ALLRAllarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement
Allarity Therapeutics, a clinical-stage biopharma company, announced that it has regained compliance with NASDAQ's minimum bid price requirement effective October 9, 2024. The company's stock has maintained a closing bid price of $1.00 or above for 20 consecutive trading days, allowing them to meet this crucial regulatory condition. CEO Thomas Jensen highlighted ongoing advancements in their stenoparib program, aimed at providing essential treatment options for advanced ovarian cancer patients. The company is focusing its resources on this promising dual-targeted inhibitor, which has shown encouraging data in its Phase 2 trial.
Read more →ALLRAllarity Therapeutics Strengthens Leadership with Key Appointments to Accelerate Stenoparib PARP Inhibitor Program
Allarity Therapeutics has announced key leadership appointments to enhance the development of its PARP inhibitor program, particularly for stenoparib. Jeremy R. Graff, Ph.D., takes on the role of President and Chief Development Officer, and Jose Iglesias, M.D., joins as Consultant Chief Medical Officer, both bringing extensive experience in oncology. Additionally, Jesper Høiland has been appointed as a Strategic Advisor to guide the company’s commercialization strategies. These appointments are aimed at accelerating clinical development and regulatory approval of stenoparib as a treatment for advanced ovarian cancer.
Read more →ALLR▼ -23.1%on this news
ALLARITY ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Allarity Therapeutics, Inc. and Encourages Investors to Contact the Firm
A class action lawsuit has been initiated against Allarity Therapeutics, alleging that the company made materially false and misleading statements regarding its operations and the regulatory status of its Dovitinib NDA. The lawsuit includes claims that Allarity and its former officers engaged in improper conduct, leading to increased scrutiny and risks of enforcement actions. Investors affected by these issues are encouraged to apply to be lead plaintiffs by November 12, 2024.
Read more →ALLRAllarity Therapeutics Announces Two Patients Now Exceeding One Year of Treatment with Stenoparib in Advanced Ovarian Cancer Trial - Durable Clinical Benefit Observed Beyond a Year on Treatment in Heavily Pre-Treated Pati
Allarity Therapeutics announced that two patients in its Phase 2 trial of stenoparib for advanced ovarian cancer have exceeded one year on treatment, demonstrating lasting clinical benefits. The patients were selected using the Drug Response Predictor (DRP) diagnostic tool, which indicated a high likelihood of success. Early results show promise in a patient population that has limited treatment options. The company plans further development of stenoparib, with ongoing evaluation of its safety and efficacy.
Read more →ALLR▲ +18.4%on this newsshared move
Allarity Therapeutics Announces New CFO and Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Allarity Therapeutics has announced the appointment of Alex Epshinsky as their new Chief Financial Officer, effective September 12, 2024. Epshinsky, who has extensive experience in biotech financial management, will play a vital role in advancing the company's projects, particularly the novel PARP inhibitor stenoparib. The company has also issued inducement grants consisting of 55,555 restricted stock units to Mr. Epshinsky to align his interests with those of the company. This strategic hire is viewed positively by the company's leadership as they continue to focus on personalized cancer therapies.
Read more →ALLR▲ +11%on this newsshared move
Allarity Therapeutics Takes Decisive Step Toward Regaining Nasdaq Compliance with Nasdaq Listing Rule 5550(a)(2)
Allarity Therapeutics has taken a significant step towards regaining compliance with Nasdaq listing requirements through a reverse stock split approved by its shareholders. The 1-for-30 reverse stock split became effective on September 11, 2024, aiming to mitigate potential delisting risks. The CEO emphasized the company's commitment to advancing its precision medicine approach, particularly focusing on stenoparib's development for advanced ovarian cancer patients.
Read more →ALLR▼ -14.5%on this news
ALLARITY THERAPEUTICS, INC. ANNOUNCEMENT: If You Have Suffered Losses in Allarity Therapeutics, Inc. (NASDAQ: ALLR), You Are to Contact The Rosen Law Firm About Your Rights
Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Allarity Therapeutics, Inc. due to allegations of materially misleading information issued by the company. The firm is preparing a class action to recover investor losses at no out-of-pocket cost. Recently, Allarity disclosed that it received a Wells Notice from the SEC, indicating ongoing investigations and potential violations of federal securities laws. This also extends to three of its former executives who have received similar notices.
Read more →ALLRAllarity Therapeutics, Inc. (ALLR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
Allarity Therapeutics, Inc. is currently facing an investigation by Bronstein, Gewirtz & Grossman, LLC regarding potential claims on behalf of its investors. The investigation follows the company's disclosure of receiving a Wells Notice from the SEC, which indicates preliminarily recommended enforcement action concerning the company's prior communications with the FDA about its New Drug Application for Dovitinib. The stock has dropped in value as a result of this news, raising concerns among investors about securities law violations.
Read more →ALLR▲ +14.9%on this news
Allarity Therapeutics Announces Postponement of Annual Stockholders Meeting
Allarity Therapeutics has announced the postponement of its Annual Meeting of Stockholders, which was scheduled for July 26, 2024. The Board of Directors made this decision just one day prior to the meeting. They plan to announce a new date for the meeting and possibly a new record date as information becomes available. This postponement may impact stockholder engagement and decision-making processes.
Read more →ALLR▲ +7.3%on this newsshared move
Allarity Encourages Shareholders to Vote FOR the Reverse Stock Split and Decrease in Authorized Shares
Allarity Therapeutics is urging its shareholders to vote in favor of a proposed reverse stock split and a decrease in authorized shares at the upcoming annual meeting. The Board of Directors believes that these measures are crucial for maintaining compliance with Nasdaq listing requirements and fostering investor confidence. A failure to secure approval could risk delisting and hinder business operations. Allarity emphasizes that the reverse stock split will not affect overall shareholder value but is necessary for strategic continuity.
Read more →ALLRAllarity Therapeutics Outlines Company's 2024 Progress and Objectives - Current Cash Balance of $20 million Expected to Provide Runway Into 2026 - Allarity to Pause Use of ATM - Cap Table Successfully Cleaned Up - Allari
Allarity Therapeutics has outlined its progress and objectives for 2024, highlighting a current cash balance of $20 million expected to sustain operations into 2026. The company has paused its At-The-Market (ATM) offering and successfully cleaned its capitalization table. Stenoparib, a drug under development for ovarian cancer, continues to show clinical benefit. However, the company received a Wells Notice from the SEC regarding potential violations of securities laws and is proposing a reverse stock split to maintain NASDAQ compliance.
Read more →ALLRAllarity Granted Hearing Before Nasdaq Panel to Present Plan of Regaining Compliance Boston (
Allarity Therapeutics, Inc. has been granted a hearing by the Nasdaq Hearings Panel to present its plans for regaining compliance with the exchange's listing requirements. This follows a notice of non-compliance related to the stock's bid price. The hearing is scheduled for approximately five weeks from now, and Allarity is diligently preparing for this meeting to present its plans. The company aims to provide updates as the process progresses.
Read more →ALLR▼ -34.8%on this newsshared move
Allarity Therapeutics' Dual PARP/Tankyrase Inhibitor, Stenoparib, Continues to Show Extended Clinical Benefit in Advanced Ovarian Cancer - Multiple patients have now exceeded 30 weeks on treatment Boston (
Allarity Therapeutics announced that its dual PARP/Tankyrase inhibitor, stenoparib, has shown extended clinical benefits in advanced recurrent ovarian cancer patients, with several individuals remaining on treatment for over 30 weeks. This follows earlier positive results where substantial tumor shrinkage and improved disease stability were reported in heavily pre-treated patients. The Company is pausing patient enrollment to refocus on accelerating regulatory approval for stenoparib. Ongoing collaboration with leading oncologists aims to refine the future trial design for this promising treatment.
Read more →ALLRAllarity Therapeutics Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement Boston (
Allarity Therapeutics has announced it has regained compliance with Nasdaq's minimum stockholders' equity requirement. This follows the company's successful cost-cutting efforts and raising new equity while reducing liabilities. CEO Thomas Jensen highlighted the fulfillment of their strategic commitments, enabling them to focus on advancing stenoparib toward regulatory approval. Additionally, a one-year mandatory panel monitor has been put in place as part of this compliance confirmation.
Read more →ALLRAllarity Therapeutics Reports First Quarter Financial Results and Highlights, including Clear Clinical Benefits from Phase 2 Trial, NASDAQ Compliance, and Significant Improvement in Cash and Equity Balances - Phase 2 Tri
Allarity Therapeutics has reported its first-quarter financial results, highlighting significant progress in its Phase 2 trial of stenoparib for advanced ovarian cancer, which showed clear clinical benefits. The company has also made strides towards compliance with Nasdaq listing requirements and improved its financial position, featuring a cash balance of $14 million. Despite these advancements, net losses and rising R&D expenses pose ongoing challenges for the company as they focus on future regulatory approvals.
Read more →ALLR▼ -18.7%on this news
Allarity Therapeutics Announces that All Series A Preferred and All Variable Priced Warrants have Converted to Common Stock - Conversions Eliminate All Variable Priced Derivative Securities - Conversions Eliminate Any Ma
Allarity Therapeutics announced that it has converted all Series A Preferred Stock and 93% of outstanding variable-priced warrants into common stock, simplifying its capital structure to a single class of shares. This strategic move was investor-initiated and eliminates any market overhang from the warrants. Additionally, the company has paid off all its bridge notes. CEO Thomas Jensen emphasized that this conversion allows the company to focus more on its developments in cancer treatments, particularly its lead asset, stenoparib.
Read more →ALLR▼ -9.9%on this news· ran to -27% by day 1shared move
Allarity Therapeutics Exceeds Nasdaq's Minimum Equity Requirement; Requests Voluntarily Withdrawal of Form S-1 - Stockholders' equity significantly surpasses the $2.5 million minimum required by Nasdaq - Company is to se
Allarity Therapeutics has announced that its stockholders' equity significantly surpasses the $2.5 million minimum equity requirement set by Nasdaq, allowing the company to regain compliance. As part of this achievement, Allarity will withdraw its Form S-1 registration statement, enabling the company to concentrate on its leading therapy, stenoparib, aimed at treating advanced ovarian cancer. The company's Drug Response Predictor (DRP) companion diagnostic is expected to enhance treatment outcomes by selecting the most likely patients to benefit from the therapy. A detailed financial disclosure will be available in the upcoming Form 10-Q, to be filed on May 14, 2024.
Read more →ALLR▼ -10.2%on this newsshared move
Allarity Therapeutics' Stenoparib Shows Clear Clinical Benefit and Achieves Significant Milestone with Early Conclusion of Phase 2 Trial in Advanced Ovarian Cancer Boston (
Allarity Therapeutics announced the early discontinuation of its Phase 2 clinical trial for stenoparib, a PARP inhibitor, in advanced ovarian cancer. The trial demonstrated significant clinical benefits, including tumor shrinkage, prompting the company to redirect resources towards a follow-on trial aimed at regulatory submission. Patients treated with stenoparib, selected using Allarity's Drug Response Predictor, showed promising results despite being heavily pretreated. The company plans to present detailed trial data as it aims to address unmet medical needs in ovarian cancer treatment.
Read more →ALLR▼ -5.5%on this news· ran to -16% by day 3shared move
Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement Boston (
Allarity Therapeutics, Inc. has successfully regained compliance with NASDAQ's minimum bid price requirement, as confirmed by a notice received on April 27, 2024. The company's stock has been closing above $1.00 per share since April 9, meeting the necessary criteria. CEO Thomas Jensen conveyed optimism about the ongoing phase 2 trial of stenoparib for treating advanced ovarian cancer, highlighting its promising early data. Allarity remains focused on developing personalized treatments for significant unmet medical needs in cancer care.
Read more →ALLR▼ -10.7%on this news
Allarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b)(1) Boston (
Allarity Therapeutics has been granted an extension by Nasdaq until May 14, 2024, to meet compliance with listing Rule 5550(b)(1). The company plans to achieve this through a comprehensive strategy that includes reducing operational costs and pursuing additional capital. Recently, Allarity also executed a 1-for-20 reverse stock split to comply with bid price requirements. CEO Thomas Jensen expressed optimism regarding their ongoing clinical trials and the support received from Nasdaq as they work to regain compliance.
Read more →ALLR▲ +5.8%on this news· ran to -23% by day 3
Allarity Therapeutics Announces 1-for-20 Reverse Stock Split Boston (
Allarity Therapeutics, Inc. has announced a 1-for-20 reverse stock split, effective April 9, 2024, to comply with Nasdaq's minimum bid price requirement. This decision follows the approval by stockholders during the 2024 Special Meeting. The reverse split aims to consolidate the number of shares, potentially aiding in operational efficiencies. However, Allarity faces challenges related to stock price volatility and fundraising for ongoing clinical trials amidst compliance pressures.
Read more →ALLRAllarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer - The stenoparib Phase 2 monotherapy trial in advanced, recurrent ova
Allarity Therapeutics has announced a strategic pivot to focus exclusively on advancing stenoparib, a novel PARP/Tankyrase dual inhibitor, towards regulatory approval for advanced recurrent ovarian cancer. This decision follows an extensive analysis of the company's opportunities and is supported by promising data from the ongoing Phase 2 trial that suggests stenoparib's clinical benefits exceed expectations. The company aims to better align its resources towards addressing an unmet medical need in this patient population while reducing ongoing costs. However, as a result of this refocus, Allarity will deprioritize other clinical trials, which may pose risks to the company's overall pipeline.
Read more →ALLRAllarity Therapeutics Receives Extension from Nasdaq Hearings Panel to Regain Compliance with Listing Rules 5550(a)(2) and 5550(b)(1) Boston (
Allarity Therapeutics has received a formal extension from the Nasdaq Hearings Panel to address compliance deficiencies regarding listing rules. The extension allows the company until April 24, 2024, to achieve a minimum bid price of $1.00 per share for at least 10 consecutive business days and to maintain stockholder equity of at least $2.5 million. The company's proactive approach includes implementing a strategic plan aimed at both meeting Nasdaq requirements and improving overall financial health. This development does not affect the trading of Allarity's stock on Nasdaq under the ticker 'ALLR'.
Read more →ALLRAllarity Therapeutics Reports Full Year 2023 Financial Results and Provides a Business Update - Leadership Changes Led by Appointment of Co-Founder Thomas Jensen as Interim CEO and Jeremy Graff, Ph.D., former Eli Lilly E
Allarity Therapeutics, Inc. announced its financial results for the fiscal year 2023, highlighting advancements in its drug development pipeline, particularly for stenoparib, a treatment for advanced ovarian cancer. Interim CEO Thomas Jensen expressed optimism about the company's potential to meet unmet medical needs in oncology. Key milestones include the anticipated release of interim data from a Phase 2 clinical trial in the second quarter of 2024. Financially, the company reported a reduced net loss compared to the previous year, reflecting improved operational performance despite ongoing challenges.
Read more →ALLRCopyright 2023 Allarity Therapeutics. All rights reserved. Nasdaq: ALLR A Gene Expression Based Biomarker For Predicting Response To Treatment Thomas Jensen, CEO Feb 2024 2 Allarity Therapeutics Legal Statement This pres
Allarity Therapeutics has unveiled its DRP Companion Diagnostics Platform, which aims to refine the prediction of cancer treatment responses through complex gene expression analysis. The platform is designed to supplement traditional biomarker technologies, thus addressing some limitations in predicting outcomes for various oncological drugs. However, the company acknowledges significant risks tied to clinical trial results, funding requirements, and possible delays due to external factors, including regulatory scrutiny and the ongoing COVID-19 pandemic.
Read more →ALLRAllarity Therapeutics to Present at Biomarkers 2024
Allarity Therapeutics, a clinical-stage biopharmaceutical company focused on personalized cancer treatments, will present its Drug Response Predictor (DRP) platform at Biomarkers 2024 in London. CEO Thomas Jensen will highlight the novel work in drug-specific companion diagnostics, particularly for ovarian cancer. The DRP platform aims to improve treatment outcomes by pre-selecting patients based on their likelihood of response to specific therapies. The presentation is scheduled for February 29, 2024.
Read more →ALLRAllarity Therapeutics Announces Thomas Jensen as Interim CEO and Appointment of Jeremy R. Graff, PhD as Key Executive Advisor
Allarity Therapeutics has announced a transition in leadership with Thomas H. Jensen appointed as Interim CEO, succeeding James G. Cullem. Alongside, Jeremy R. Graff, PhD, has been engaged as a key Executive Advisor, bringing over 25 years of experience in cancer therapeutics. Jensen's background as a co-founder and his operational experience is expected to ensure a smooth transition. The leadership changes aim to continue advancing Allarity's development in personalized cancer care through its innovative DRP® companion diagnostic technology.
Read more →ALLRRS\ULJKW $OODULW\7KHUDSHXWLFV$OOULJKWVUHVHUYHG 1DVGDT$//5 Personalized Cancer Care. Realized. James G. Cullem, CEO H2 2023 Allarity Therapeutics Legal Statement This presentation is provided for informational purposes on
Allarity Therapeutics is making strides in developing its oncology pipeline, notably through its lead candidate, Stenoparib, which is undergoing Phase 2 trials for ovarian cancer. The company emphasizes the importance of drug-specific companion diagnostics to enhance patient selection and therapeutic effectiveness. However, potential risks, including funding challenges and uncertainties in clinical outcomes, may impact their progress. Allarity's strategic focus on precision oncology underlines its commitment to personalized cancer care.
Read more →ALLRAllarity’s Early Phase 2 Stenoparib Data Indicates Clinical Benefit in Women with Advanced Ovarian Cancer Selected with DRP Companion Diagnostic
Allarity Therapeutics reported promising early results from its Phase 2 trial of stenoparib for women with advanced ovarian cancer. Among evaluable patients, one experienced a complete response and others showed stable disease. The trial utilized the DRP®-Stenoparib CDx to select patients, indicating that targeted therapy may provide benefits despite previous treatments. However, early data are preliminary and may change as the study progresses.
Read more →ALLRAll evaluable participants, with prior PARP inhibitor therapy and chemotherapy, showed significant tumor shrinkage including one complete response - Early data follows Phase 2 dose optimization change from once-daily to
Allarity Therapeutics announced promising initial results from its ongoing Phase 2 trial of stenoparib for advanced ovarian cancer. Among the five evaluable patients, one achieved a complete response and four showed stable disease. The trial utilizes Allarity's DRP -Stenoparib CDx to screen patients likely to benefit from the treatment. Findings suggest that the twice-daily dosing schedule may optimize drug exposure, with an interim readout expected in Q1 2024.
Read more →ALLRCopyright 2023 Allarity Therapeutics. All rights reserved. Nasdaq: ALLR Personalized Cancer Care. Realized. James G. Cullem, CEO H2 2023 Legal Statement Allarity Therapeutics 2 This presentation is provided for informati
Allarity Therapeutics provided an update on its clinical pipeline, including insights into the efficacy of Stenoparib, a dual PARP and Tankyrase inhibitor for ovarian cancer. The company emphasizes the role of companion diagnostics in identifying patients most likely to benefit from its treatments. However, it also acknowledges various risks, including the need for sufficient capital to fund ongoing clinical trials and the uncertainties surrounding regulatory approvals and trial outcomes. Forward-looking statements highlight expectations that may not materialize due to inherent uncertainties.
Read more →ALLRAllarity Therapeutics to Present at Biomarkers Europe 2023
Allarity Therapeutics, Inc. is set to present at Biomarkers Europe 2023, focusing on their development of drug-specific DRP® companion diagnostics. Their presentation will discuss a gene expression-based biomarker for predicting response to treatment with Dovitinib and Ixabepilone. In addition to the presentation, Allarity will participate in a panel discussion alongside representatives from Merck and Roche. The event is scheduled for November 14-15, 2023, in Berlin, Germany.
Read more →ALLRAllarity Therapeutics CEO Letter to Shareholders BOSTON
Allarity Therapeutics' CEO reflected on the challenges and achievements of the past year in a letter to shareholders. Despite a decline in market capitalization, the company managed to raise $18.5 million, which will support ongoing clinical trials, including new combination therapies. The letter highlights encouraging clinical data from its DRP diagnostics platform and emphasizes the company's commitment to personalized cancer care. Furthermore, the recent expansion of the Board of Directors signals a strengthened commitment to corporate governance and strategic growth.
Read more →ALLRAllarity Therapeutics and FivepHusion Announce Collaboration to Support Clinical Development of Deflexifol™ with DRP Companion Diagnostics
Allarity Therapeutics has formed a Clinical Collaboration Agreement with FivepHusion to support the clinical development of Deflexifol™, a novel formulation of 5-fluorouracil. The collaboration will utilize Allarity's drug-specific DRP® companion diagnostics to identify eligible patients for forthcoming clinical trials. FivepHusion plans to initiate a phase 1b/2a study in late 2023 aimed at treating unresectable metastatic colorectal cancer. The agreement includes provisions for the analysis of patient biopsies to assess treatment efficacy and optimize treatment protocols.
Read more →ALLRAllarity Therapeutics Strengthens Board of Directors with Appointment of Three Accomplished Biotechnology Executives - New appointments bring therapeutic development expertise and proven leadership to support continued p
Allarity Therapeutics has appointed three experienced biotechnology executives to its Board of Directors, effective August 1, 2023. Laura Benjamin, Robert Oliver, and Joseph Vazzano bring substantial expertise in oncology and pharmaceutical development. This restructuring aims to enhance the Board's independence and support Allarity's growth and compliance with Nasdaq listing requirements. Their appointments are expected to provide strategic guidance for the company's drug development efforts toward personalized cancer therapies.
Read more →ALLRAllarity Therapeutics Strengthens Board of Directors with Appointment of Three Accomplished Biotechnology Executives
Allarity Therapeutics announced the appointment of three seasoned biotechnology executives to its Board of Directors, effective August 1, 2023. The new members, Laura Benjamin, Robert Oliver, and Joseph Vazzano, bring extensive experience in therapeutic development, corporate leadership, and financial management. This restructuring aims to enhance the company's strategic guidance and ensure compliance with Nasdaq's continued listing requirements. Allarity is focused on developing novel oncology therapeutics supported by its Drug Response Predictor companion diagnostics.
Read more →ALLRAllarity Therapeutics, Inc. Announces Pricing of $11 Million Public Offering BOSTON, MA (
Allarity Therapeutics, Inc. announced the pricing of an $11 million public offering to support its oncology therapeutic developments. The offering includes 2,444,445 shares priced at $4.50 each, with warrants to purchase an equal number of shares. Proceeds will be allocated towards clinical trials, outstanding liabilities, and general corporate purposes. This offering is set to close around July 10, 2023, subject to customary conditions.
Read more →ALLRInitial Data from Allarity's Phase 2 Trial of IXEMPRA Indicate Potential for Improved Clinical Benefit in DRP -Selected Metastatic Breast Cancer Patients Boston, MA (
Allarity Therapeutics has announced promising initial results from its Phase 2 trial of IXEMPRA for metastatic breast cancer patients selected using the DRP-IXEMPRA companion diagnostic. Among the evaluable patients, significant clinical benefits were observed, suggesting a higher response rate than previously recorded. However, these findings are still in preliminary stages, and statistical significance has yet to be established. The company aims to refine the diagnostic criteria further to enhance patient selection for this treatment.
Read more →ALLRAllarity Therapeutics Announces Reverse Stock Split of Common Stock - Common Stock Will Begin Trading on a Post-Split Adjusted Basis on
Allarity Therapeutics has announced a reverse stock split of its common stock at a ratio of 1-for-40, effective June 28, 2023. This decision comes after stockholder approval to amend the company's Certificate of Incorporation to facilitate the split. The company aims to increase its share price to comply with Nasdaq's listing requirements and support its efforts to raise additional capital. Following the split, the number of outstanding shares will decrease significantly, affecting all shareholders uniformly.
Read more →ALLRAllarity Therapeutics Announces Reverse Stock Split of Common Stock
Allarity Therapeutics announced a reverse stock split of its common stock at a ratio of 1-for-40, effective at 4:05 p.m. on June 28, 2023. This decision was approved by stockholders during a special meeting held on June 23, 2023. The split aims to increase the trading price per share and achieve compliance with Nasdaq's minimum share price requirement. The reverse stock split will reduce the outstanding shares significantly but will not alter the overall percentage of ownership for shareholders.
Read more →ALLRAllarity Therapeutics Announces Clarification of Effective Date for Reverse Stock Split
Allarity Therapeutics has issued a press release to clarify the effective date of its planned reverse stock split, which was initially expected to take place on June 27, 2023. The reverse split aims to raise the company's share price to comply with Nasdaq's listing requirements and assist in raising additional capital. Stockholders had approved the proposal to allow the Board to determine the specific split ratio, which will range from 1-for-15 to 1-for-50. The effective date will be announced in a future release.
Read more →ALLRAllarity Therapeutics Announces Adjournment of Special Meeting of Stockholders Meeting adjourned to Friday
Allarity Therapeutics announced the adjournment of its special meeting of stockholders originally scheduled for June 20, 2023, now postponed to June 23, 2023. This adjournment is intended to allow more time for stockholders to approve the proposals detailed in the company's proxy statement. Stockholders who have already submitted their votes are not required to vote again, and the meeting will take place virtually.
Read more →ALLRAllarity Therapeutics Announces Adjournment of Special Meeting of Stockholders
Allarity Therapeutics has announced the adjournment of its special meeting of stockholders, originally scheduled for June 20, 2023, to June 23, 2023. This decision was made to allow more time for the company to secure approvals on key proposals outlined in its proxy statement. The adjourned meeting will be conducted virtually, and stockholders who have already voted will not need to re-cast their votes. The company continues to encourage stockholders to participate in the voting process.
Read more →ALLRAllarity Therapeutics, Inc. Announces Pricing of $7.5 Million Public Offering BOSTON, MA (
Allarity Therapeutics, Inc. has announced a public offering priced at $7.5 million, consisting of common stock and warrants. The company intends to utilize proceeds for various financial obligations, including paying off accounts payable and accrued liabilities. The offering is expected to close on or about April 21, 2023, dependent on customary conditions being met.
Read more →ALLRAbstract Evaluating Allarity's DRP Companion Diagnostic for Cisplatin Accepted at 2023 ASCO Annual Meeting Poster presentation focused on a Phase 2 Clinical Study Evaluating the Utility of a DRP Com
Allarity Therapeutics announced that its abstract showcasing the DRP Companion Diagnostic for cisplatin has been accepted for presentation at the 2023 ASCO Annual Meeting. The presentation will highlight a Phase 2 clinical study that focuses on identifying patients with metastatic breast cancer who could benefit from treatment with LiPlaCis, a formulation of cisplatin. Conducted in partnership with Danish hospitals and Smerud Medical Research International AS, the study demonstrates the potential effectiveness of the DRP technology in tailoring cancer treatment based on a patient's genetic profile.
Read more →ALLRAllarity Therapeutics Provides Updates for IXEMPRA and Stenoparib Phase 2 Monotherapy Clinical Studies Efforts underway to accelerate patient recruitment and amend protocols to improve patient outcomes. Int
Allarity Therapeutics has provided updates on its Phase 2 clinical studies evaluating IXEMPRA and stenoparib as monotherapies. The company is working to accelerate patient recruitment and has amended protocols to improve outcomes and increase participant eligibility. Despite challenges from slower enrollment, partly due to COVID, Allarity expects interim data readouts for both studies by the end of 2023. These changes reflect the company's commitment to enhancing patient benefit in cancer treatment.
Read more →ALLRAllarity Therapeutics Provides Updates for IXEMPRA and Stenoparib Phase 2 Monotherapy Clinical Studies
Allarity Therapeutics has provided updates on its Phase 2 clinical programs for IXEMPRA and stenoparib, both being examined as monotherapies. The company is making strides to accelerate patient recruitment, including expanding collaborations with contract research organizations and modifying trial protocols to increase eligible participants. Despite previous delays attributed to the COVID-19 pandemic, Allarity is optimistic about achieving interim data readouts for both studies by the end of 2023, reflecting its commitment to patient benefit and personalized cancer treatment.
Read more →ALLRAllarity Therapeutics Announces Reverse Stock Split of Common Stock Common Stock Will Begin Trading on a Post-Split Adjusted Basis on
Allarity Therapeutics has announced a reverse stock split of its common stock at a ratio of 1-for-35. This decision follows approval from stockholders during a special meeting on March 20, 2023. The stock split will become effective on March 24, 2023, intended to increase the per share trading price and assist in compliance with Nasdaq listing requirements. The adjustment will reduce the outstanding shares from approximately 34.3 million to around 979,846 shares.
Read more →ALLRAllarity Therapeutics Doses First Patient in Phase 1b Clinical Trial Evaluating Dovitinib and Stenoparib Combination in Advanced Solid Tumors Company anticipates that the combination of pan-TKI dovitinib an
Allarity Therapeutics has initiated a Phase 1b clinical trial that has successfully dosed its first patient, testing the combination of dovitinib and stenoparib on advanced solid tumors. This trial marks a strategic shift towards combination therapies aimed at improving treatment outcomes for patients, particularly those with ovarian cancer. The study will assess the safety and efficacy of the drug combination and is expected to generate insights into synergistic benefits. Initial results are anticipated in the first half of 2024, positioning Allarity to address critical treatment gaps.
Read more →ALLRAllarity Therapeutics Doses First Patient in Phase 1b Clinical Trial Evaluating Dovitinib and Stenoparib Combination in Advanced Solid Tumors
Allarity Therapeutics has initiated the Phase 1b clinical trial for a combination therapy involving dovitinib and stenoparib, targeting advanced solid tumors, including ovarian cancer. This trial represents a shift in Allarity's clinical strategy towards combination therapies that aim to address unmet medical needs. The study will evaluate the safety, anti-cancer activity, and maximum tolerated doses of both drugs in up to 36 patients. The trial's design incorporates Allarity's proprietary DRP® companion diagnostics to identify patients who are likely to respond favorably to treatment, with data readouts expected in the first half of 2024.
Read more →ALLRAllarity Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders
Allarity Therapeutics announced the adjournment of its 2023 Annual Meeting of Stockholders, originally scheduled for January 19, 2023. The meeting has been postponed to February 3, 2023, to provide additional time for stockholders to vote on the proposals outlined in the definitive proxy statement. Stockholders who have already voted do not need to take further action, while those who have yet to vote are encouraged to do so promptly. The meeting will be held virtually, and the method for participation remains the same as initially communicated.
Read more →ALLRAllarity Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders Boston, MA U.S.A. (
Allarity Therapeutics has announced the adjournment of its 2023 Annual Meeting of Stockholders, which was initially scheduled for January 19, 2023. The meeting will now reconvene on February 3, 2023, to give stockholders additional time to vote on the proposals presented in the Proxy Statement. The company encourages stockholders who have not yet participated in the voting to do so to facilitate decision-making at the reconvened meeting.
Read more →ALLRAllarity Therapeutics Reschedules 2022 Annual Stockholders Meeting and Sets New Record Date Boston, MA U.S.A. (
Therapeutics Reschedules 2022 Annual Stockholders Meeting Sets New Record Date Boston, MA U.S.A. (December 1, 2022) - Allarity Therapeutics, Inc. ("Allarity" or the "Company"), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-s
Read more →ALLRAllarity Therapeutics Reschedules 2022 Annual Stockholders Meeting and Sets New Record Date
Boston, MA U.S.A. (December 1, 2022) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, today announced th
Read more →ALLRAllarity Therapeutics Reports Third Quarter 2022 Financial Results Cambridge, MA U.S.A. (
Allarity Therapeutics Reports Third Quarter 2022 Financial Results Cambridge, MA U.S.A. (November 15, 2022) - Allarity Therapeutics, Inc. ("Allarity" or the "Company"), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific
Read more →ALLRAllarity Therapeutics Announces Adjournment of 2022 Annual Meeting of Stockholders Cambridge, MA U.S.A. (
Allarity Therapeutics Announces Adjournment of 2022 Annual Meeting Cambridge, MA U.S.A. (November 7, 2022) - Allarity Therapeutics, Inc. ("Allarity" or the "Company"), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific D
Read more →ALLRAllarity Therapeutics Announces Adjournment of 2022 Annual Meeting of Stockholders
Cambridge, MA U.S.A. (November 7, 2022) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care today announced
Read more →ALLRAllarity Therapeutics Reports Second Quarter 2022 Financial Results, Provides Recent Operational Highlights, and Regains Compliance with NASDAQ Listing Requirements Cambridge, MA U.S.A. (
Allarity Therapeutics Reports Second Quarter 2022 Financial Results, Provides Recent Operational Highlights, and Regains Compliance with NASDAQ Listing Requirements Cambridge, MA U.S.A. (October 11, 2022) - Allarity Therapeutics, Inc. ("Allarity" or the "Company"), a clinica
Read more →ALLRAllarity Therapeutics Appoints Seasoned Biotechnology Executive Jerry McLaughlin to Board of Directors Cambridge, MA U.S.A. (
Allarity Therapeutics Appoints Seasoned Biotechnology Jerry McLaughlin to Board of Directors Cambridge, MA U.S.A. (September 26, 2022) - Allarity Therapeutics, Inc. (Nasdaq: ALLR) ("Allarity" or the "Company"), a clinical-stage pharmaceutical company developing novel oncology
Read more →ALLRAllarity Therapeutics Appoints Seasoned Biotechnology Executive Jerry McLaughlin to Board of Directors
Cambridge, MA U.S.A. (September 26, 2022) — Allarity Therapeutics, Inc. (Nasdaq: ALLR) (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care
Read more →ALLRAllarity Therapeutics to Present at Ladenburg Thalmann Healthcare Conference
Cambridge, MA U.S.A. (September 16, 2022) — Allarity Therapeutics, Inc. (Nasdaq: ALLR) (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care
Read more →ALLRAllarity Therapeutics Announces Appointment of New Auditor Cambridge, MA U.S.A. (
Allarity Therapeutics Announces Appointment of New Cambridge, MA U.S.A. (September 12, 2022) - Allarity Therapeutics, Inc. (Nasdaq: ALLR) ("Allarity" or the "Company"), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific D
Read more →ALLRAllarity Therapeutics Announces Appointment of New Auditor
Cambridge, MA U.S.A. (September 12, 2022) — Allarity Therapeutics, Inc. (Nasdaq: ALLR) (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care
Read more →ALLRAllarity Therapeutics Receives Nasdaq Notification of Non-Compliance with Listing Rule 5250(c)(1) Cambridge, MA U.S.A. (
Allarity Therapeutics Receives Nasdaq Notification with Listing Rule 5250(c)(1) Cambridge, MA U.S.A. (August 26, 2022) - Allarity Therapeutics, Inc. (Nasdaq: ALLR) ("Allarity" or the "Company"), a clinical-stage pharmaceutical company developing novel oncology therapeutics to
Read more →ALLRAllarity Therapeutics Receives Nasdaq Notification of Non-Compliance with Listing Rule 5250(c)(1)
Cambridge, MA U.S.A. (August 26, 2022) — Allarity Therapeutics, Inc. (Nasdaq: ALLR) (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, t
Read more →ALLRAllarity Therapeutics (NASDAQ: ALLR): Diamond in the Rough
NY City, New York, United States, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Diamond in the Rough Click here for full length version of article. Allarity Therapeutics, Inc. (NASDAQ: ALLR) is a clinical stage oncology therapeutics company founded in Denmark in 2004 by Chief Scientific Of
Read more →ALLRCopyright 2022 Allarity Therapeutics. All rights reserved. Nasdaq: ALLR Personalized Cancer Care. Realized. James G. Cullem, CEO H2 2022 2 Allarity Therapeutics Legal Statement This presentation is provided for informati
2 Allarity Therapeutics Legal Statement This presentation is provided for informational purposes only and is subject to change. The information contained herein doe s n ot purport to be all - inclusive. The data contained herein is derived from various internal and external sourc
Read more →ALLRAllarity Therapeutics Refocuses Oncology Pipeline Strategy Towards Combination Therapies
New strategy aligns with ongoing shift in oncology standard-of-care towards combination therapies Combination therapy focus expected to improve the Company’s future funding and commercial prospects New pipeline strategy follows Type C meeting held with FDA regarding dovitini
Read more →ALLRAllarity Therapeutics Refocuses Oncology Pipeline Strategy Towards Combination Therapies New strategy aligns with ongoing shift in oncology standard-of-care towards combination therapies Combination therapy
Allarity Therapeutics Refocuses Oncology Pipeline Strategy Towards Combination Therapies with ongoing shift in oncology standard-of-care towards combination therapies focus expected to improve the Company's future funding and commercial prospects New pipeline strategy follows
Read more →ALLRAllarity Therapeutics Bolsters Its Board of Directors with Appointment of Prominent Clinical Researcher and Oncology Drug Developer, David A. Roth, M.D. Interim CEO James G. Cullem, J.D. and Co-Founder Thom
Allarity Therapeutics Bolsters Its Board of Directors with Appointment of Prominent Clinical Researcher and Oncology Drug Developer, Interim CEO James G. Cullem, J.D. and Co-Founder Thomas Jensen also joining the Board Cambridge, MA, U.S.A. (July 11, 2022) - Allarity Therape
Read more →ALLRAllarity Therapeutics Bolsters Its Board of Directors with Appointment of Prominent Clinical Researcher and Oncology Drug Developer, David A. Roth, M.D.
Interim CEO James G. Cullem, J.D. and Co-Founder Thomas Jensen also joining the Board Cambridge, MA, U.S.A. (July 11, 2022) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with d
Read more →ALLRAllarity Therapeutics Announces Executive Leadership Transition
Board Appoints James G. Cullem, J.D., to Interim Chief Executive Officer, Joan Y. Brown, CPA, to Interim Chief Financial Officer Cambridge, MA, U.S.A. (June 29, 2022) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing
Read more →ALLRAllarity Therapeutics Announces Executive Leadership Transition Board Appoints James G. Cullem, J.D., to Interim Chief Executive Officer, Joan Y. Brown, CPA, to Interim Chief Financial Officer Cambridge, MA
Allarity Therapeutics Announces Executive Leadership Transition Board Appoints James G. Cullem, J.D., to Interim Chief Executive Officer, to Interim Chief Financial Officer Cambridge, MA, U.S.A. (June 29, 2022) - Allarity Therapeutics, Inc. ("Allarity" or the "Company"), a
Read more →ALLRAllarity Therapeutics Strengthens Scientific Advisory Board with Appointment of Distinguished Oncologist Roberto Pili, M.D.
Cambridge, MA U.S.A. (June 15, 2022) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, today announced th
Read more →ALLRAllarity Therapeutics Reports First Quarter 2022 Financial Results Cambridge, MA U.S.A. (
Allarity Therapeutics Reports First Quarter 2022 Financial Results Cambridge, MA U.S.A. (May 27, 2022) - Allarity Therapeutics, Inc. ("Allarity" or the "Company"), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP c
Read more →ALLRCopyright 2022 Allarity Therapeutics. All rights reserved. Nasdaq: ALLR Personalized Cancer Care. Realized. Steve R. Carchedi, CEO H1 2022 2 Allarity Therapeutics Legal Statement This presentation is provided for informa
2 Allarity Therapeutics Legal Statement This presentation is provided for informational purposes only and is subject to change. The information contained herein doe s n ot purport to be all - inclusive. The data contained herein is derived from various internal and external sourc
Read more →ALLRCorrection Notice to Press Release Announcing Financial Results For the Fourth Quarter and Full Year 2021 Financial Results and Corporate Update Cambridge, MA U.S.A. (
Correction Notice to Press Release Announcing Financial Results For the Fourth Quarter and Full Year 2021 Financial Results and Corporate Update Cambridge, MA U.S.A. (May 18, 2022) - Allarity Therapeutics, Inc. (NASDAQ: ALLR) announced today that its press release issued unde
Read more →ALLRAllarity Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update Cambridge, MA U.S.A. (
Allarity Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update Cambridge, MA U.S.A. (May 16, 2022) - Allarity Therapeutics, Inc. ("Allarity" or the "Company"), a clinical-stage pharmaceutical company developing novel oncolog
Read more →ALLRAllarity Therapeutics Provides Update on Dovitinib Program
Allarity has requested a Type C meeting with the FDA to discuss potential clinical paths to support approval of dovitinib in view of the regulatory agency’s recent Refusal to File letters for the Company’s NDA and related PMA Allarity intends to announce the results of the Typ
Read more →ALLRAllarity Therapeutics Receives Refusal to File Letters from U.S. FDA
Refusal to File letters concern the new drug application for dovitinib and the DRP®-Dovitinib companion diagnostic pre-market approval application Allarity intends to seek guidance from the FDA on how to further advance dovitinib and its accompanying DRP®-Dovitinib companion di
Read more →ALLRCopyright 2022 Allarity Therapeutics. All rights reserved. N a sdaq: A L LR Personalized Cancer Care. Realized. Steve R. Carchedi, CEO H1 2022 Legal Statement 1 /1 4 /2 0 2 2 Allarity Therapeutics 2 This presentation is
Legal Statement 1 /1 4 /2 0 2 2 Allarity Therapeutics 2 This presentation is provided for informational purposes only and is subject to change. The information contained herein does not purport to be all - inclusive. The data contained herein is derived from various internal and
Read more →ALLRAllarity Therapeutics and Oncoheroes Biosciences Sign Agreements to Advance Pediatric Cancer Development of Dovitinib and Stenoparib Oncoheroes will fund and advance the clinical development of both dovitin
Therapeutics and Oncoheroes Biosciences Sign Agreements to Advance Pediatric Cancer Development of Dovitinib and Stenoparib Oncoheroes will fund and advance the clinical development of both dovitinib and stenoparib in pediatric cancers, utilizing Allarity's DRP companion diag
Read more →ALLRAllarity Therapeutics and Oncoheroes Biosciences Sign Agreements to Advance Pediatric Cancer Development of Dovitinib and Stenoparib
Oncoheroes will fund and advance the clinical development of both dovitinib and stenoparib in pediatric cancers, utilizing Allarity’s DRP® companion diagnostics Allarity has submitted a new drug application (NDA) for the U.S. approval of dovitinib in renal cell carcinoma (RCC) t
Read more →ALLR▲ +20.2%on this news
Allarity Therapeutics Submits New Drug Application (NDA) to the U.S. FDA for Dovitinib for Third-Line Treatment of Renal Cell Carcinoma (RCC)
Marks Allarity’s first regulatory application for marketing approval for one of its prioritized oncology pipeline programs NDA is supported by Allarity’s previously-filed pre-market approval (PMA) submission to the FDA for the Dovitinib-DRP® companion diagnostic to select RCC
Read more →ALLRAllarity Therapeutics Closes Its Recapitalization, Share Exchange, and $20M PIPE Investment; Lists on U.S. Nasdaq Stock Market Cambridge, MA U.S.A. (
Allarity Therapeutics Closes Its Recapitalization, Share Exchange, and $20M PIPE Investment; Lists on U.S. Nasdaq Stock Market Cambridge, MA U.S.A. (December 21, 2021) - Allarity Therapeutics, Inc. ("Allarity" or the "Company"), a clinical-stage biopharmaceutical company dev
Read more →ALLRAllarity Therapeutics Closes Its Recapitalization, Share Exchange, and $20M PIPE Investment; Lists on U.S. Nasdaq Stock Market
Cambridge, MA U.S.A. (December 21, 2021) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage biopharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, today annou
Read more →ALLRAllarity Therapeutics Announces Delisting and Last Day of Trading in the Company’s Shares on Nasdaq First North
Hørsholm, Denmark (December 13, 2021) — Allarity Therapeutics A/S (“Allarity A/S” or the “Company”) today announced that Nasdaq First North Growth Market Sweden (“Nasdaq First North”) has accepted the Company’s application to delist the shares of Allarity A/S. Allarity A/S submit
Read more →ALLRAllarity Therapeutics Announces Shareholder Acceptance of Share Swap Offer and Initiates Delisting of the Company’s Shares from Nasdaq First North
Hørsholm, Denmark (December 11, 2021) — Allarity Therapeutics A/S (“Allarity A/S” or the “Company”) today announced that in excess of 94 % of the Company’s shareholders have accepted the Share Swap Offer, announced on November 24 and expired on December 9, pending final reconcili
Read more →ALLRAllarity Therapeutics A/S Publishes Offer Document Offering to Acquire Company Shares in Exchange for Shares in Allarity Therapeutics, Inc. with the Intent to Complete Recapitalization
Hørsholm, Denmark (November 24, 2021) — Allarity Therapeutics A/S ("Allarity A/S" or the "Company") hereby announces a voluntary offer and offer document to the shareholders of Allarity A/S to acquire all shares in Allarity A/S (the "Offer"), with the intent of completing the Com
Read more →ALLRAllarity Therapeutics Publishes Interim Report for the Period January – September 2021
Hørsholm, Denmark (November 23, 2021) – Allarity Therapeutics A/S (“Allarity” or the “Company”) today announces the publication of its Interim Report for the period January – September 2021. The report is available as an attached document and on the company’s website. Steve Carc
Read more →ALLRAllarity Therapeutics’ Oral PARP Inhibitor, Stenoparib, Demonstrates Pre-clinical Antiviral Activity Against Delta Variant of Coronavirus
Current positive results with delta variant B.1.617.2 follows previous pre-clinical tests, including testing of alpha variant B.1.1.7 (“British” variant), beta variant B.1351 (“South African” variant), and gamma variant P.1 (“Brazilian” variant). Allarity Therapeutics is planni
Read more →ALLRAllarity Therapeutics and Lonza Collaborate to Manufacture Dovitinib, a Renal Cell Carcinoma Candidate
Integrated solution for process development and manufacturing of drug substance and drug product will facilitate the advancement of clinical development The agreement meets Allarity’s needs for current and future commercial production of dovitinib and will support the Company’s
Read more →ALLRAllarity Therapeutics Presents Dovitinib Survival Data from DRP Screened RCC Patients at ESMO 2021 Virtual Congress
Patient selection using DRP® score of 50% resulted in a median survival of 15.0 month Patient selection using DRP® score of 67% resulted in a median survival of 20.6 months Hørsholm, Denmark (September 16, 2021) – Allarity Therapeutics A/S (“Allarity” or the “Company”) today an
Read more →ALLRAllarity Therapeutics Receives Approximately SEK 16.5 Million (US $1.9 Million) from Subscription to Warrants of Series ALLR TO 3
Subscription is approximately 6.7 percent of total outstanding TO 3 warrants Allarity’s Chairman of the Board and largest shareholder (Sass & Larsen ApS) participated in the subscription Hørsholm, Denmark (September 14, 2021) – Allarity Therapeutics A/S (“Allarity” or the “Comp
Read more →ALLRAllarity Therapeutics Announces Extraordinary Exercise Period for Warrants of Series ALLR TO 3 Set to August 30 – September 13, 2021
Hørsholm, Denmark (August 26, 2021) – Allarity Therapeutics A/S (“Allarity” or the “Company”) today announces that an accelerated extraordinary and final exercise period for warrants of the ALLR TO 3 series (the “TO 3 Warrants”), which were issued to subscribers of units in the C
Read more →ALLRAllarity Therapeutics Publishes Interim Report for the Period January – June 2021
Hørsholm, Denmark (August 23, 2021) – Allarity Therapeutics A/S (“Allarity” or the “Company”) today announces the publication of its Interim Report for the period January – June 2021. The report is available as an attached document and on the Company’s website. Steve Carchedi, C
Read more →ALLRAllarity Therapeutics Files Form S-4 Registration Statement with U.S. Securities & Exchange Commission (SEC) for Listing on U.S. Nasdaq
Company anticipates the first day of trading on U.S. Nasdaq will be during the fourth A previously-announced U.S. $20 million investment by 3i Fund supports Company’s transition to the U.S. Nasdaq Hørsholm, Denmark (August 23, 2021) — Allarity Therapeutics A/S (“Allarity” or th
Read more →ALLRAllarity Therapeutics Elaborates on the Contents of the Meeting Agenda for the Extraordinary General Meeting Announced on August 16, 2021
Hørsholm, Denmark (August 18, 2021) – Allarity Therapeutics A/S (“Allarity” or the “Company”) yesterday published a notice to convene an Extraordinary General Meeting on August 31, 2021. The Company hereby further elaborates on the information provided in the notice. Based on qu
Read more →ALLRAllarity Therapeutics’ oral PARP inhibitor, Stenoparib, demonstrates additional pre-clinical antiviral activity against new variants of Coronavirus
Current positive results with 3 variants, including alpha variant B.1.1.7 (“British” variant), beta variant B.1351 (“South African” variant) and gamma variant P.1 (“Brazilian” variant), follows prior pre-clinical tests indicating efficacy of the novel PARP inhibitor stenoparib ag
Read more →ALLRAllarity Therapeutics and Lantern Pharma Enter into Agreement for Future Clinical Development of Irofulven
Lantern will reacquire global rights to Irofulven and assume full authority to manage and guide future clinical and commercial development of the program Hørsholm, Denmark and Dallas, TX, U.S.A. (July 26, 2021) – Allarity Therapeutics A/S (“Allarity”) and Lantern Pharma Inc. (“L
Read more →ALLRAllarity Therapeutics Issues Share Units as Payment-In-Kind for Services Rendered During Rights Issue in Q2 2021
Issuance of share Units fullfils payment obligations to guarantors and coordinator/bookrunner of Rights Issue conducted in Q2 2021 Hørsholm, Denmark (14 July 2021) Allarity Therapeutics A/S (“Allarity” or the “Company”) today announced a payment-in-kind and a debt conversion str
Read more →ALLRAllarity Therapeutics Receives Acceptance & Review Notification from U.S. FDA for Pre-Market Approval Application for Dovitinib-DRP
Administrative acceptance review notification of pre-market approval (PMA) application is first step in multi-step process conducted by the FDA The PMA is submitted in support of an imminent new drug application (NDA) for dovitinib Hørsholm, Denmark (5 July 2021) — Allarity The
Read more →ALLRAllarity Therapeutics and Oncoheroes Biosciences to Partner on Pediatric Cancer Development of Dovitinib and Stenoparib
Oncoheroes will fund and advance clinical development of both dovitinib and stenoparib in pediatric cancers Allarity is preparing to file a first U.S. new drug application (NDA) for the approval of dovitinib in renal cell carcinoma (RCC), and has been planning for an additional
Read more →ALLRAllarity Therapeutics Completes Oversubscribed Rights Issue
– Allarity raises SEK 102.8 million before issue costs to further finance the development of three high-priority pipeline programs – The Rights Issue of Units was subscribed for approximately 106 percent, without the use of guarantors’ commitments Hørsholm, Denmark (10 June 2
Read more →ALLRAllarity Therapeutics Publishes E-Poster Detailing the Molecular Pathways Covered by the Dovitinib-DRP Companion Diagnostic
– Poster title: A novel drug response predictor (DRP®) mRNA biomarker for the multi tyrosine kinase inhibitor dovitinib – Poster provides new details of the DRP® companion diagnostic for dovitinib, its lead oncology pipeline asset Hørsholm, Denmark (9 June 2021) Allarity Therap
Read more →ALLRAllarity Therapeutics Publishes Interim Report for the Period January – March 2021
Hørsholm, Denmark (28 May 2021) Allarity Therapeutics A/S (“Allarity” or the “Company”) today announces the publication of its Interim Report for the period January – March 2021. The report is available as an attached document and on the company’s website. Steve Carchedi, CEO of
Read more →ALLRAllarity Therapeutics Publishes Prospectus Supplement
Hørsholm, Denmark (27 May 2021) — Allarity Therapeutics A/S (“Allarity” or the “Company”) today announced that the Company’s Board of Directors has approved a Supplement to the Prospectus regarding the invitation to subscribe for shares in the Company’s Offering, which was approv
Read more →ALLRAllarity Therapeutics Secures Investment from 3i Fund for Recapitalization, Transition to Listing on U.S. Nasdaq, and Advancing Pipeline of Priority Oncology Therapeutics
US $20 million investment by 3i Fund is conditioned upon completion of the recapitalization into a newly organized Delaware holding company (Allarity Therapeutics, Inc.) and a listing of its common stock on the U.S. Nasdaq Stock Market The recapitalization and reorganization wit
Read more →ALLRAllarity Therapeutics to Conduct a Rights Issue of New Shares, and Publishes Prospectus regarding the Rights Issue
- Proceeds will finance further development of three high-priority programs - More than SEK 100 million covered by subscription undertakings and guarantee commitments Hørsholm, Denmark (19 May 2021) Allarity Therapeutics A/S (“Allarity” or the “Company”) today announced that it
Read more →ALLRAllarity Therapeutics Updates Preliminary Timetable for Planned Rights Issue
Hørsholm, Denmark (5 May 2021) Allarity Therapeutics A/S (“Allarity” or the “Company”) today announced an update of the preliminary timetable for the planned Rights Issue announced on 23 March 2021. Updated preliminary timetable for the Rights Issue 17 May 2021: Publication of
Read more →ALLRAllarity Therapeutics To Present a Dovitinib-DRP e-Poster at the European Association for Cancer Research (EACR) 2021 Virtual Congress
- Poster title: A novel drug response predictor (DRP®) mRNA biomarker for the multi tyrosine kinase inhibitor dovitinib - Poster provides new details of the DRP® companion diagnostic for dovitinib, its lead oncology pipeline asset Hørsholm, Denmark (29 April 2021) Allarity Ther
Read more →ALLRAllarity Therapeutics Submits Premarket Approval Application to U.S. FDA for DRP Companion Diagnostic for Dovitinib
- Submission precedes expected NDA filing for dovitinib in 2021 - Premarket Approval will allow U.S. marketing of DRP-Dovitinib as companion diagnostic to dovitinib Hørsholm, Denmark (2 April 2021) Allarity Therapeutics A/S (“Allarity” or the “Company”) today announced the subm
Read more →ALLRAllarity Therapeutics Publishes its Annual Report for 2020
Hørsholm, Denmark (31 March 2021) – Allarity Therapeutics A/S (“Allarity” or the “Company”) today announces the issuance of its Annual Report for 2020. The report is available as an attached document and on the Company’s website. Comment from CEO Steve Carchedi Steve Carchedi,
Read more →ALLRAllarity Therapeutics plans fully guaranteed rights issue of approximately SEK 100 million
- Proceeds will finance further development of three high-priority programs - Rights Issue is fully covered by subscription undertakings and guarantee commitments - The Company will discontinue the use of convertible notes Hørsholm, Denmark (23 March 2021) Allarity Therapeutic
Read more →ALLRAllarity Therapeutics Announces Positive Data from Preclinical Study of Dovitinib in Osteosarcoma
- Treatment of animal osteosarcoma models with dovitinib increased the median survival time by 50 % as compared to control animals. Hørsholm, Denmark (9 March 2021) – Allarity Therapeutics A/S (“Allarity” or the “Company”) today announced positive data from its preclinical asse
Read more →ALLRAllarity Therapeutics Initiates Phase 2 Trial of IXEMPRA in Europe for the Treatment of Metastatic Breast Cancer
Hørsholm, Denmark (4 March 2021) – Allarity Therapeutics A/S (“Allarity” or the “Company”) today announced that it has enrolled the first patient in its European Phase 2 clinical trial of IXEMPRA® (ixabepilone) for the treatment of metastatic breast cancer. The U.S. Food and Dru
Read more →ALLRAllarity Therapeutics Provides Update on Pre-Clinical Testing of Stenoparib’s Antiviral Activity Against New Variants of Coronavirus
-Current testing follows preceding pre-clinical tests indicating efficacy of the novel PARP inhibitor stenoparib against SARS-Cov-2, the virus which is the origin of the B.1.1.7 variant, B.1.351 variant, and other variants. -Allarity Therapeutics is one of the leading companies
Read more →ALLRAllarity Therapeutics Draws Down the Fourth Tranche Under Its Convertible Note Agreement with Negma Group LTD and Park Partners GP
Hørsholm, Denmark (11 February 2021) – Allarity Therapeutics A/S (“Allarity” or the “Company”) today announced that it has called upon the fourth tranche of SEK 10 million under its existing financing facility with Negma Group LTD and Park Partners GP (“Negma/Park”), in line with
Read more →ALLRAllarity Therapeutics to test activity of its PARP inhibitor, stenoparib, as a potential therapy for new highly infectious Strain B.1.1.7 of Coronavirus
Hørsholm, Denmark (26 January 2021) – Allarity Therapeutics A/S (“Allarity” or the “Company”) today announced plans to further test the antiviral activity of stenoparib, its PARP inhibitor, against SARS-CoV-2 lineage B.1.1.7, also known as Coronavirus Variant B117 (the “British v
Read more →ALLRAllarity Therapeutics issues new shares to Aalto Capital in connection with services rendered
Hørsholm, Denmark (22 January 2021) – Allarity Therapeutics A/S (“Allarity” or the “Company”) today announces the issue of 516,262 new shares to Aalto Capital in connection with services rendered as part of capital advisory agreement. The Company has, based on a Board resolution
Read more →ALLRAllarity Therapeutics Draws Down the Third Tranche Under Its Convertible Note Agreement with Negma Group LTD and Park Partners GP
Hørsholm, Denmark (22 December 2020) – Allarity Therapeutics A/S (“Allarity” or the “Company”) today announced that it has called upon the third tranche of SEK 10 million under its existing financing facility with Negma Group LTD and Park Partners GP (“Negma/Park”), in line with
Read more →ALLRAllarity Therapeutics Expands its Stenoparib License Rights to Include Anti-Viral Uses
Hørsholm, Denmark (14 December 2020) – Allarity Therapeutics A/S (“Allarity” or the “Company”) today announced that it has amended its license agreement with Eisai Co., Ltd. (Tokyo, Japan) to expand Allarity’s field-of-use to include anti-viral uses of Stenoparib (formerly E7449)
Read more →ALLRAllarity Therapeutics Publishes Interim Report for the Period January – September 2020
Hørsholm, Denmark (30 November 2020) – Allarity Therapeutics A/S (“Allarity” or the “Company”) today announces the Interim Report for the period January – September 2020. The report is available as an attached document and on the company’s website. Steve Carchedi, CEO of Oncolog
Read more →ALLRAllarity Therapeutics Draws Down the Second Tranche Under Its Convertible Note Agreement with Negma Group LTD and Park Partners GP
Hørsholm, Denmark (5 November 2020) – Allarity Therapeutics A/S (“Allarity” or the “Company”) today announced that it has called upon the second tranche of SEK 10 million under its existing financing facility with Negma Group LTD and Park Partners GP (“Negma/Park”), in line with
Read more →ALLRAllarity Therapeutics Hires New Chief Financial Officer
Hørsholm, Denmark (November 4, 2020) – Allarity Therapeutics A/S (“Allarity” or the “Company”) today announced that Jens Erik Knudsen, CPA, MBA, has been appointed as its new Chief Financial Officer (CFO), effective immediately. He brings to Allarity a unique combination of exper
Read more →ALLRAllarity Therapeutics Gains Allowance from U.S. Patent and Trademark Office for New DRP Biomarker Patents
Hørsholm, Denmark (26 October 2020) – Allarity Therapeutics A/S (“Allarity” or the “Company”) today announced that the United States Patent and Trademark Office (USPTO) has issued Notices of Allowance to the Company for three new DRP® biomarker patents in conjunction with use of
Read more →ALLRAllarity Therapeutics will trade under new short name ALLR starting on 12 October 2020
Hørsholm, Denmark (9 October 2020) – Allarity Therapeutics A/S (“Allarity” or the “Company”) today announced that following the Company’s name change from Oncology Venture A/S to Allarity Therapeutics A/S, the Company will be trading under its new short name ALLR from Monday, 12
Read more →Competitive Position
How ALLR ranks across every disease it competes inCompetitive Position is a premium feature
See how ALLR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial